This phase I/II trial is trying to understand how safe a type of targeted drug therapy is in order to determine an appropriate amount to use alone or in combination with other drugs in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer.
This trial is treating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer
Eligible patients will receive REGN4018 as a monotherapy or in combination with cemiplimab in a series of dose escalation cohorts over 6-week cycles.
Recruiting Hospitals Read More